BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 9078349)

  • 1. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
    Shizuru JA; Jerabek L; Edwards CT; Weissman IL
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts.
    Uchida N; Tsukamoto A; He D; Friera AM; Scollay R; Weissman IL
    J Clin Invest; 1998 Mar; 101(5):961-6. PubMed ID: 9486965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitating cells enable engraftment of purified fetal liver stem cells in allogeneic recipients.
    Gaines BA; Colson YL; Kaufman CL; Ildstad S
    Exp Hematol; 1996 Jul; 24(8):902-13. PubMed ID: 8690049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoblasts promote engraftment of allogeneic hematopoietic stem cells.
    El-Badri NS; Wang BY; Cherry ; Good RA
    Exp Hematol; 1998 Feb; 26(2):110-6. PubMed ID: 9472800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic cell transplantation for the induction of allo- and xenotolerance.
    Sykes M
    Clin Transplant; 1996 Aug; 10(4):357-63. PubMed ID: 8884109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
    Jankowski RA; Ildstad ST
    Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells.
    Scheffold C; Scheffold YC; Cao TM; Gworek J; Shizuru JA
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):1-12. PubMed ID: 15625539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
    Sykes M; Sheard M; Sachs DH
    J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
    Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
    J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.